ARS Pharmaceuticals combines explosive post-launch revenue growth with a confirmed technical downtrend, heavy cash burn, and unusually high short interest, making it a high-risk bet on continued commercial execution.
Thesis pillars
- Confirmed Technical Downtrend→Stable
- Strong Post Launch Revenue Growth→Stable
- Implausible Analyst Target Rejected→Stable
- +2 more pillars — see the Why tab for full reasoning
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.10: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 34%; Elevated put/call ratio: 2.58; Below-average business quality.
ARS Pharmaceuticals is a commercial-stage biopharmaceutical company whose only approved product, neffy, is the first needle-free intranasal epinephrine treatment for Type I allergic reactions including anaphylaxis, approved in the U.S., EU, U.K., Japan, Australia, and China. The... Read more
Sell if holding. Engine safety override at $8.10: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 34%; Elevated put/call ratio: 2.58; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Score 5.2/10, moderate confidence.
Passes 4/9 gates (clean insider activity, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and news soft leadership change. Suitability: speculative.
About ARS Pharmaceuticals, Inc.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals derives its entire commercial existence from a single product: neffy, the first and only FDA-approved needle-free intranasal epinephrine treatment for Type I allergic reactions, which the company states is its only product that has been approved for sale. The FDA approved neffy 2 mg in August 2024 and neffy 1 mg in March 2025, and the product has since gained approval in the EU, U.K., Japan, Australia, and China, representing markets covering approximately 98% of global epinephrine autoinjector sales. As of February 2026, more than 22,500 U.S. physicians had prescribed neffy, with approximately 93% overall commercial insurance coverage.
ARS commercializes neffy in the U.S. through a 106-person direct sales force plus roughly 70 co-promotion reps from partner ALK-Abelló targeting pediatricians, supplemented by direct-to-consumer advertising and the getneffy.com virtual-prescriber platform launched in November 2025. Payer access remains a work in progress: approximately 57% of commercial coverage requires no prior authorization and only 8 of 50 state Medicaid programs cover neffy without prior authorization, though the company has secured broader coverage, inclusive of prior-authorization plans, of about 93%. Outside the U.S., ARS licenses neffy to Alfresa in Japan, Pediatrix in China, Seqirus in Australia and New Zealand, and ALK in the EU, U.K., Canada, and other unpartnered territories, earning milestone payments and royalties rather than direct sales; EURneffy has already launched in Germany (June 2025) and the U.K. (October 2025). Beyond anaphylaxis, ARS is running a Phase 2b trial in chronic spontaneous urticaria, with interim data expected in the second half of 2026 and a pivotal study potentially starting in mid-2027.
Show full overview
Because neffy is ARS's only approved product, the 10-K frames nearly every operational risk as a neffy risk: the company has never commercialized a product before September 2024, depends on ALK U.S.'s sales force (which it does not control) to reach pediatricians, and depends on Alfresa, Pediatrix, Seqirus, and ALK to execute launches across Japan, China, Australia, and Europe that ARS itself will not directly manage. That structure means neffy's commercial trajectory is really four or five separate execution bets happening in parallel across different partners and geographies, any one of which underperforming would show up directly in ARS's royalty and milestone revenue without a second product to offset it.
See also: Healthcare · Biotechnology
From ARS Pharmaceuticals, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — ARS Pharmaceuticals, Inc.
Latest news
- NEWS ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective — benzinga Jul 7, 2026 negative
Generated 2026-07-08T22:53:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineneffy10-K Item 1A: 'neffy is our only product that has been approved for sale.'
Material Events(8-K, last 90d)
- 2026-05-13Item 5.02LOWBoard appointed Donn Casale (formerly Chief Commercial Officer at Dynavax Technologies) as President, effective on his start date (expected June 1, 2026); CEO Richard Lowenthal previously held the President title. Routine executive hire, no departure involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Volatile — 9.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.10: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: High short interest: 34%; Elevated put/call ratio: 2.58; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 37, MACD bearish. Prior stop was $7.53. Score 5.2/10, moderate confidence.
Take-profit target: $10.65 (+31.5% upside). Prior stop was $7.53. Stop-loss: $7.53.
Concentration risk — Pipeline: neffy; DATA_ISSUE: analyst_target_implausible (raw $29.25 vs price $8.10 — ratio 3.6×). Rejected, falling back to technical TP.; Quality below floor (3.7 < 4.0).
ARS Pharmaceuticals, Inc. trades at a P/E of N/A (forward -9.8). TrendMatrix value score: 4.6/10. Verdict: Sell.
10 analysts cover SPRY with a consensus score of 4.4/5. Average price target: $29.
What does ARS Pharmaceuticals, Inc. do?ARS Pharmaceuticals is a commercial-stage biopharmaceutical company whose only approved product, neffy, is the first...
ARS Pharmaceuticals is a commercial-stage biopharmaceutical company whose only approved product, neffy, is the first needle-free intranasal epinephrine treatment for Type I allergic reactions including anaphylaxis, approved in the U.S., EU, U.K., Japan, Australia, and China. The company commercializes neffy in the U.S. directly and through a co-promotion deal with ALK-Abelló, while licensing ex-U.S. rights to Alfresa (Japan), Pediatrix (China), Seqirus (Australia/New Zealand), and ALK (other territories including the EU, U.K., and Canada).